Onxeo S.A. buy metanicnor
Summary
This prediction ended on 16.03.17 with a price of €2.50. The prediction for Onxeo S.A. disappointed with a performance of -19.61%. metanicnor has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Onxeo S.A. | 5.360% | 5.360% | -61.745% | -83.830% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
Comments by metanicnor for this prediction
In the thread Onxeo S.A. diskutieren
onxeo
die am weitesten fortgeschrittenen Biotechnologie in Frankreich, aber nur 128 Millionen von Kapitalisierung €: onxeo verkauft drei Medikamente: Beleodaq, Sitavig & Loramyc®
Onxeo nicht starten eine einzige Phase III Validive
am Ende des Dezember 2016 Cash Flow betrug € 33.800.000 so nächste Spendenaktion wird Mitte 2017 sein
die ersten Ergebnisse der Phase III von Livatag sollte fallen im Jahr 2017 beginnen
Aurgalys ist € 11,12
cm cic Wertpapiere ist 10,2 €
edison ist 8,3 €
Invest Securities ist 8 €
invest ist 11 € von 2014.04.08
Oddo ist 9 €